Metastat RGCC is an advanced test to detect specific blood-borne markers that can accurately determine whether a secondary cancerous tumour is likely to develop and its potential location.

During the test, we analyse a sample of a patient’s blood in our state-of-the-art laboratory to analyse, identify and measure circulating tumour cells (CTCs).

Metastat RGCC is suitable for all patients who have received a confirmed cancer diagnosis. The test can accurately detect the development of secondary cancers or tumours and improve personalised cancer treatments.